<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01146470</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC-10-NV-0176-CTIL</org_study_id>
    <secondary_id>RGC</secondary_id>
    <nct_id>NCT01146470</nct_id>
  </id_info>
  <brief_title>The Influence of Red Grape Cells on Blood Pressure Vascular Function in People With Hypertension</brief_title>
  <acronym>RGC</acronym>
  <official_title>A Single-Center, Double-blind, Random, Parallel Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fruitura Bioscience Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that 3 Months Daily Supplementation of RGC will effect blood pressure
      and vascular function.

      This will be a single-center, double-blind, random, parallel controlled Study. Study
      population will include 60 subjects, who will be divided randomly into three groups. The
      first group will get RGC 200mg, the second group will get RGC 400mg, and the third group will
      get 200mg placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the influence of RGC on blood pressure and vascular function.</measure>
    <time_frame>3 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in oxidative stress parameters</measure>
    <time_frame>3 months of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>RGC 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RGC 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>RGC</intervention_name>
    <description>dosage of Red Grape Cells once a day, during 3 months</description>
    <arm_group_label>RGC 200 mg</arm_group_label>
    <arm_group_label>RGC 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>dosage of Placebo once a day, during 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 35-70

          -  BMI &lt; 40.0 kg/m2

          -  Blood pressure: SYS. ≤154 mmHg, DIA. ≤93 mmHg.

        Exclusion Criteria:

          -  Breastfeeding or pregnancy.

          -  Milk allergy - the substance may contain traces of milk protein (casein).

          -  Taking anti-hypertensive medications.

          -  Taking antioxidant food supplements, excluding probiotic agents and fibers (taken for
             less than two weeks before beginning the study).

          -  Subjects suffering from any of the following conditions: cardiovascular disorders,
             renal disorders, intestinal disorders, hepatic disease, malignant or autoimmune
             diseases or other metabolic diseases.

          -  A subject whose baseline blood tests indicate abnormalities in hepatic or renal
             function, thyroid function or blood count.

          -  Unusual eating habits.

          -  The subject is in the process of active weight loss / gain.

          -  Addiction to drugs / alcohol.

          -  Medically documented psychiatric problems or neurological disorders.

          -  Smokers. (Subjects who quit smoking more than two years ago may be included in the
             study).

          -  Systolic blood pressure above 154 mmHg.

          -  Diastolic blood pressure above 93 mmHg.

          -  Taking phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction
             (Viagra, Cialis, etc.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nachum Vaisman, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel-Aviv Sourasky Medical Center, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tel Aviv Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2010</study_first_submitted>
  <study_first_submitted_qc>June 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2010</study_first_posted>
  <last_update_submitted>February 17, 2013</last_update_submitted>
  <last_update_submitted_qc>February 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

